Modified oncolytic virus
AssigneeReplimune Limited GB
InventorRobert Stuart Coffin
Life of this patent
Estimating the term…
Abstract
The present invention relates to an oncolytic virus comprising: (i) a fusogenic protein-encoding gene and (ii) an immune stimulatory molecule-encoding gene.
Claims26
An oncolytic herpes simplex virus (HSV) comprising inserted in its genome:
- (i) a heterologous gene encoding a fusogenic glycoprotein from gibbon ape leukemia virus (GALV) from which the R peptide has been mutated or removed (GALV-R-), (ii) a heterologous gene encoding an anti-CTLA-4 antibody or an antigen binding fragment thereof, and (iii) one or more heterologous genes encoding any of a CD40 ligand, 4-1-BB ligand, GITR ligand, OX40 ligand, ICOS ligand and flt3 ligand.
An oncolytic herpes simplex virus (HSV), which is a modified HSV1 strain RH018A having the accession number ECACC 16121904, comprising inserted in its genome a heterologous gene encoding a fusogenic glycoprotein from gibbon ape leukemia virus (GALV) from which the R peptide has been mutated or removed (GALV-R-), a heterologous gene encoding an anti-CTLA-4 antibody or an antigen binding fragment thereof, a heterologous gene encoding a CD40 ligand and a heterologous gene encoding a 4-1-BB ligand, wherein the heterologous genes encoding GALV-R- and an anti-CTLA-4 antibody are inserted into the ICP34.5 encoding locus of the oncolytic virus genome such that the oncolytic virus does not express functional ICP34.5, and wherein the ICP47-encoding gene is deleted such that the US11 gene is under the control of the ICP-47 immediate early gene promoter.
Dependencies are inferred from the claim text.